Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: dr.praveen who wrote (5602)	1/17/2007 12:33:25 PM
From: keokalani'nui	Read Replies (1) \| Respond to of 12215

Nice!

To: dr.praveen who wrote (5602)	1/17/2007 12:43:11 PM
From: tuck	Read Replies (1) \| Respond to of 12215

BioCryst's Charlie Bugg : "From what I have read, the total antiviral package for 2006 which is at $200 million. Now this is the only announcement I am aware of that they funded so there's a little bit over half their total allocation for new antiviral. " He said this on January 4th, 2007, after BioCryst announced an award from DHHS of $106 million. So, unclear to me if the Iomai award is part of the 2006 budget -- in which case that's the end -- or if it's in the 2007 budget, in which case more contracts could be awarded. I have no idea how the HHS budget works in this area. Given the difference in products they may not really be competitors. And since Iomai's contract doesn't really involve a new antiviral, it may be an entirely different budget. Thus not sure if this squeezes out other contenders. AVII seems to be down a bit. If that is in reaction to the news, it was telegraphed a couple of hours ahead of Iomai's announcement. Cheers, Tuck